Evidence map›Paper›PMID 39176175›Full record

ArticleMolecular therapy. Nucleic acids2024

IL-12 and PD-1 peptide combination gene therapy for the treatment of melanoma.

Loree C Heller, Guilan Shi, Amanda Sales Conniff, Julie Singh, Samantha Mannarino, Jody Synowiec, Richard Heller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Loree C HellerDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Guilan ShiDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Amanda Sales ConniffDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Julie SinghDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Samantha MannarinoDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Jody SynowiecDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.
Richard HellerDepartment of Medical Engineering, University of South Florida, Morsani College of Medicine and College of Engineering, 12901 Bruce B. Downs Blvd., MDC111, Tampa, FL 33612, USA.

Funding

Efficient Delivery of Plasmid DNA to Achieve Appropriate Transgene ExpressionR01CA186730 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI HELLER, RICHARD · 2015 to 2019
$1.8M
DNA-specific pattern recognition receptor activation following DNA electroporationR01CA196796 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI HELLER, LOREE C · 2016 to 2020
$1.6M
NCI NIH HHS R01 CA186730NCI NIH HHS R01 CA196796
6 · The paper itself

Abstract

Interleukin-12 (IL-12) gene electrotransfer (GET) delivery is highly effective in inducing long-term, complete regression in mouse and human melanoma and other solid tumors. Therapeutic efficacy is enhanced by immune checkpoint inhibitors, and the combination of IL-12 plasmid GET (pIL-12 GET) and anti-programmed cell death protein 1 (PD-1) monoclonal antibodies has reached clinical trials. In this study, we designed peptides and plasmids encoding the mouse homologs of the pembrolizumab and nivolumab programmed cell death 1 ligand 1 (PD-L1) binding regions. We hypothesized that intratumor autocrine/paracrine peptide expression would block PD-1/PD-L1 binding and provide cancer patients with an effective and cost-efficient treatment alternative. We demonstrated that the mouse homolog to pembrolizumab was effective at blocking PD-1/PD-L1

Indexed as

gene electrotransferimmune checkpoint inhibitorinterleukin 12MT: Delivery Strategies

Identifiers

PMID39176175
PMCPMC11339250

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.